Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 07, 2015 12:53 AM ET


Company Overview of Celladon Corporation

Company Overview

Celladon Corporation, a clinical-stage biotechnology company, focuses on developing cardiovascular gene therapy and calcium dysregulation. The company’s lead product candidate includes MYDICAR that uses genetic enzyme replacement therapy to correct the Sarco/endoplasmic reticulum Ca 2+ -ATPase 2a enzyme deficiency in heart failure patients that result in inadequate pumping of the heart. Its MYDICAR product is used to treat patients with systolic heart failure, diastolic heart failure, and advanced heart failure, as well as to treat pulmonary arterial hypertension and arteriovenous fistula maturation failure. The company is also developing membrane-bound form of Stem Cell Factor for the treat...

11988 El Camino Real

Suite 650

San Diego, CA 92130

United States

Founded in 2000

23 Employees





Key Executives for Celladon Corporation

Chief Executive Officer and Director
Age: 58
Total Annual Compensation: $189.7K
Vice President, General Counsel and Secretary
Age: 44
Total Annual Compensation: $233.8K
Vice President of Corporate Development & Investor Relations
Age: 44
Total Annual Compensation: $190.4K
Vice President of Corporate Operations
Age: 54
Total Annual Compensation: $216.3K
Vice President of Clinical Operations
Age: 53
Total Annual Compensation: $216.3K
Compensation as of Fiscal Year 2014.

Celladon Corporation Key Developments

Pomerantz LLP Announces Class Action Lawsuit Against Celladon Corporation

Pomerantz LLP announced that a class action lawsuit has been filed against Celladon Corporation and certain of its officers. The class action, filed in United States District Court, Southern District of California, is on behalf of a class consisting of all persons or entities who purchased Celladon securities between July 7, 2014 and June 25, 2015 inclusive (class period).  This class action seeks to recover damages against defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934. If users are a shareholder who purchased Celladon securities during the class period, the user will have until August 31, 2015 to ask the Court to appoint user as Lead Plaintiff for the class. The complaint alleged that throughout the class period, defendants made false and misleading statements and/or failed to disclose adverse information regarding the prospects for MYDICAR, the company's first most promising investigational drug for heart failure patients.

Celladon Corporation Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Celladon Corporation reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported loss from operations of $16,075,000 compared to $7,005,000 a year ago. Consolidated net loss was $16,525,000 compared to $6,992,000 a year ago. For the six months period, the company reported loss from operations of $32,372,000 compared to $13,929,000 a year ago. Consolidated net loss was $33,271,000 compared to $14,154,000 a year ago.

Celladon Appoints Wedbush As Financial Advisor For Sale Process

Celladon Corporation (NasdaqGM:CLDN) announced the engagement of Wedbush Securities Inc. as its exclusive financial advisor and a strategic plan pursuant to which it immediately commenced a process to seek a merger or sale.

Similar Private Companies By Industry

Company Name Region
Integrative Stem Cell Institute United States
Edwards Environmental Corporation United States
BioCee, Inc. United States
Inception 4, Inc. United States
Genia Technologies, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Celladon Corporation, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at